277 related articles for article (PubMed ID: 17522247)
21. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
[TBL] [Abstract][Full Text] [Related]
22. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
23. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
24. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
[TBL] [Abstract][Full Text] [Related]
26. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
27. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
28. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
[TBL] [Abstract][Full Text] [Related]
29. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
30. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Glaspy J
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
[TBL] [Abstract][Full Text] [Related]
32. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
33. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
Vansteenkiste JF
Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
[TBL] [Abstract][Full Text] [Related]
34. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
Eisterer W; Hussl C; Erb H; Haslbauer F; Sormann S; Braun S; Jaeger C
Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611
[TBL] [Abstract][Full Text] [Related]
35. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
Vansteenkiste J; Poulsen E; Rossi G; Glaspy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):45-55. PubMed ID: 12435173
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
37. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
Kotasek D; Steger G; Faught W; Underhill C; Poulsen E; Colowick AB; Rossi G; Mackey J;
Eur J Cancer; 2003 Sep; 39(14):2026-34. PubMed ID: 12957457
[TBL] [Abstract][Full Text] [Related]
38. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
39. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
Folloder J
Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
[TBL] [Abstract][Full Text] [Related]
40. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]